For some survivors, uncontrollable gain weight can be a consequence of a brain injury. The condition, known as acquired hypothalamic obesity, strikes when there is damage to the hypothalamus, the brain region that regulates hunger and energy balance. Once that control center is disrupted, patients are left with relentless hunger and rapid weight gain that resists diet and exercise alone. (Most often, the condition follows treatment for brain tumors, but traumatic brain injuries and strokes can trigger it too.)

Those with this condition previously have nowhere to turn for real help, but that changed on March 19, 2026: the U.S. Food and Drug Administration approved setmelanotide, sold as Imcivree, as the first therapy specifically designated for this rare disease. The drug works by restoring hormone signaling along the MC4R pathway, which is the same circuit the injury disrupts.
The approval followed the largest placebo-controlled study ever conducted for this condition, published in the New England Journal of Medicine on July 8, 2026. Patients on the drug saw a 16.5 percent average drop in BMI, compared with a 3.3 percent increase among those on the placebo. Trial co-author Dr. Reema Habiby confirms, “These results offer real hope to children and families who have had very few options.”










